Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 16 entities : Eli lilly and company save search
ReCode Therapeutics Appoints Angèle Maki, Ph.D., as Senior Vice President of Business Development
Published: 2021-08-16 (Crawled : 13:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
ev
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study
Published: 2021-08-16 (Crawled : 13:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.53%
H: 0.72%
C: 0.68%
therapy phase 3
FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps
Published: 2021-08-16 (Crawled : 12:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
fda injection insulin fda approval
Insulet Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States
Published: 2021-08-16 (Crawled : 12:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
PODD | $167.18 1.68% 1.65% 550K
|
Health Technology
|
| O: 2.16%
H: 2.81%
C: 2.29%
fda clearance fda insulin clearance
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Published: 2021-08-16 (Crawled : 07:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
dermatitis phase 3 skin trial atopic dermatitis clearance
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2021-08-16 (Crawled : 00:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.53%
H: 0.72%
C: 0.68%
treatment therapy phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.